TG Therapeutics Company Profile (NASDAQ:TGTX)

About TG Therapeutics

TG Therapeutics logoTG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TGTX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.60
  • 50 Day Moving Average: $4.83
  • 200 Day Moving Average: $5.83
  • 52-Week Range: $4.10 - $10.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.34
  • P/E Growth: 0.00
  • Market Cap: $322.91M
  • Outstanding Shares: 54,731,000
  • Beta: 2.1
Profitability:
  • Net Margins: -47,494.08%
  • Return on Equity: -83.18%
  • Return on Assets: -70.72%
Debt:
  • Current Ratio: 4.23%
  • Quick Ratio: 4.23%
Additional Links:
Companies Related to TG Therapeutics:

Analyst Ratings

Consensus Ratings for TG Therapeutics (NASDAQ:TGTX) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.68 (284.32% upside)

Analysts' Ratings History for TG Therapeutics (NASDAQ:TGTX)
Show:
DateFirmActionRatingPrice TargetDetails
2/22/2017AegisInitiated CoverageBuy$26.00View Rating Details
12/6/2016FBR & CoSet Price TargetBuy$24.00View Rating Details
12/7/2016Roth CapitalSet Price TargetBuy$33.00View Rating Details
10/15/2016HC WainwrightReiterated RatingBuy$22.00 -> $18.00View Rating Details
10/15/2016Ladenburg Thalmann Financial ServicesReiterated RatingBuy$28.00View Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$28.00View Rating Details
8/24/2016S&P Equity ResearchLower Price Target$7.15 -> $6.40View Rating Details
5/27/2016SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$7.22 -> $18.00View Rating Details
9/9/2015Raymond James Financial, Inc.Initiated CoverageStrong-Buy$20.00View Rating Details
6/20/2015MLV & Co.Set Price TargetBuy$22.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for TG Therapeutics (NASDAQ:TGTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/7/2016Q3($0.31)($0.50)ViewListenView Earnings Details
8/8/2016Q2($0.29)($0.33)ViewN/AView Earnings Details
5/10/2016Q1($0.36)($0.28)ViewListenView Earnings Details
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details
11/9/2015Q3($0.34)($0.28)ViewN/AView Earnings Details
8/10/2015Q215($0.32)($0.38)ViewListenView Earnings Details
5/5/2015Q115($0.33)($0.39)$38.10 millionViewN/AView Earnings Details
3/11/2015Q414($0.26)($0.48)ViewN/AView Earnings Details
11/10/2014Q214($0.32)($0.51)$38.10 millionViewN/AView Earnings Details
7/22/2014($0.28)($0.36)ViewN/AView Earnings Details
5/12/2014Q114($0.19)($0.25)ViewN/AView Earnings Details
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.62)$0.03 million$0.04 millionViewN/AView Earnings Details
8/1/2013Q213($0.16)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TG Therapeutics (NASDAQ:TGTX)
Current Year EPS Consensus Estimate: $-1.42 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.37)($0.37)($0.37)
Q2 20162($0.29)($0.26)($0.28)
Q3 20163($0.33)($0.26)($0.29)
Q4 20163($0.40)($0.30)($0.36)
Q1 20171($0.40)($0.40)($0.40)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.36)($0.36)($0.36)
Q4 20171($0.37)($0.37)($0.37)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TG Therapeutics (NASDAQ:TGTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for TG Therapeutics (NASDAQ:TGTX)
Insider Ownership Percentage: 19.00%
Institutional Ownership Percentage: 50.08%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Sean A. PowerCFOSell8,816$4.55$40,112.80View SEC Filing  
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00View SEC Filing  
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90View SEC Filing  
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TG Therapeutics (NASDAQ:TGTX)
DateHeadline
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in TG Therapeutics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline (NASDAQ:TGTX)
finance.yahoo.com - February 25 at 7:45 PM
finance.yahoo.com logoIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm (NASDAQ:TGTX)
finance.yahoo.com - February 25 at 7:45 PM
finance.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Rentech, Inc. Investors and Encourages Investors to Contact the Firm (NASDAQ:TGTX)
finance.yahoo.com - February 24 at 11:57 AM
us.rd.yahoo.com logoTG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology (NASDAQ:TGTX)
us.rd.yahoo.com - February 22 at 10:16 AM
us.rd.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:TGTX)
us.rd.yahoo.com - February 22 at 10:16 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG ... - Yahoo Finance (NASDAQ:TGTX)
finance.yahoo.com - February 21 at 4:45 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG ... - Yahoo Finance (NASDAQ:TGTX)
finance.yahoo.com - February 21 at 4:45 PM
News IconTG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab ... - P&T Community (NASDAQ:TGTX)
www.ptcommunity.com - February 21 at 4:45 PM
streetinsider.com logoTG Therapeutics (TGTX) Announces Publication of Data from Phase 1/2 Trial of TG-1101 - StreetInsider.com (NASDAQ:TGTX)
www.streetinsider.com - February 21 at 4:45 PM
News IconStock Price Target in Spotlight: TG Therapeutics, Inc. (NASDAQ:TGTX) - Rockville Register (NASDAQ:TGTX)
rockvilleregister.com - February 20 at 7:16 PM
4-traders.com logoCeprotec group of companies marks National Sport Day (NASDAQ:TGTX)
www.4-traders.com - February 18 at 9:07 AM
News IconThe Law Offices of Vincent Wong (NASDAQ:TGTX)
www.enhancedonlinenews.com - February 16 at 8:01 PM
businesswire.com logoBragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) and Encourages Investors with Losses to Contact ... (NASDAQ:TGTX)
www.businesswire.com - February 16 at 8:01 PM
us.rd.yahoo.com logoTGTX SHAREHOLDER REMINDER: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:TGTX)
us.rd.yahoo.com - February 16 at 8:01 PM
us.rd.yahoo.com logoURGENT: Monteverde & Associates PC Encourages TG Therapeutics, Inc. Shareholders with Losses To Contact The Firm Immediately - TGTX (NASDAQ:TGTX)
us.rd.yahoo.com - February 16 at 8:01 PM
finance.yahoo.com logoBragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) and Encourages Investors with Losses to Contact the Firm (NASDAQ:TGTX)
finance.yahoo.com - February 15 at 6:29 AM
News IconConsensus Buys According to Analysts: TG Therapeutics, Inc. (NASDAQ:TGTX) - Rockville Register (NASDAQ:TGTX)
rockvilleregister.com - February 13 at 8:43 PM
globenewswire.com logoTG Therapeutics, Inc. to Present at the 2017 BIO CEO & Investor Conference - GlobeNewswire (press release) (NASDAQ:TGTX)
globenewswire.com - February 11 at 5:21 AM
finance.yahoo.com logoTGTX UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:TGTX)
finance.yahoo.com - February 11 at 5:21 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:TGTX)
finance.yahoo.com - February 11 at 5:21 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX (NASDAQ:TGTX)
finance.yahoo.com - February 11 at 5:21 AM
feeds.benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX (NASDAQ:TGTX)
feeds.benzinga.com - February 10 at 8:30 PM
finance.yahoo.com logoTG Therapeutics, Inc. to Present at the 2017 BIO CEO & Investor Conference (NASDAQ:TGTX)
finance.yahoo.com - February 10 at 6:04 AM
us.rd.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of TG Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm (NASDAQ:TGTX)
us.rd.yahoo.com - February 6 at 9:21 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:TGTX)
us.rd.yahoo.com - February 6 at 9:21 PM
us.rd.yahoo.com logoSafirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against TG Therapeutics - TGTX (NASDAQ:TGTX)
us.rd.yahoo.com - February 6 at 9:21 PM
us.rd.yahoo.com logoBragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) and Encourages Investors to Contact the Firm (NASDAQ:TGTX)
us.rd.yahoo.com - February 6 at 9:21 PM
us.rd.yahoo.com logoINVESTOR ALERT: Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of TG Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm (NASDAQ:TGTX)
us.rd.yahoo.com - February 5 at 7:59 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, … (NASDAQ:TGTX)
finance.yahoo.com - February 4 at 8:21 PM
us.rd.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm (NASDAQ:TGTX)
us.rd.yahoo.com - February 4 at 8:21 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In TG Therapeutics, Inc. (TGTX) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NASDAQ:TGTX)
us.rd.yahoo.com - February 4 at 8:21 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX (NASDAQ:TGTX)
us.rd.yahoo.com - February 4 at 8:21 PM
openpr.com logoTG Therapeutics Inc (NASDAQ:TGTX) Investor Lawsuit alleges Securities Laws Violations (NASDAQ:TGTX)
www.openpr.com - February 2 at 6:02 AM
finance.yahoo.com logoTGTX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:TGTX)
finance.yahoo.com - February 2 at 6:02 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:TGTX)
finance.yahoo.com - February 2 at 6:02 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 … (NASDAQ:TGTX)
finance.yahoo.com - January 31 at 3:53 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm (NASDAQ:TGTX)
finance.yahoo.com - January 31 at 3:53 AM
News IconVolatility Watch on Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Gilbert Daily (NASDAQ:TGTX)
gilbertdaily.com - January 30 at 11:08 AM
globenewswire.com logoTGTX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG ... - GlobeNewswire (press release) (NASDAQ:TGTX)
globenewswire.com - January 29 at 2:30 AM
4-traders.com logoKhang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:TGTX)
www.4-traders.com - January 28 at 6:57 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:TGTX)
finance.yahoo.com - January 28 at 6:57 AM
feeds.benzinga.com logoTGTX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:TGTX)
feeds.benzinga.com - January 27 at 12:53 PM
streetinsider.com logoTG Therapeutics (TGTX) Receives Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 to Treat DLBCL (NASDAQ:TGTX)
www.streetinsider.com - January 25 at 6:39 AM
us.rd.yahoo.com logoTG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for the Treatment of Diffuse Large B-cell Lymphoma (NASDAQ:TGTX)
us.rd.yahoo.com - January 25 at 6:39 AM
us.rd.yahoo.com logo7:42 am TG Therapeutics confirms that the FDA has granted orphan drug designation covering the combination of TG-1101 (ublituximab) for the treatment of diffuse large b-cell lymphoma (NASDAQ:TGTX)
us.rd.yahoo.com - January 25 at 6:39 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against TG Therapeutics, Inc. and Certain Officers – TGTX (NASDAQ:TGTX)
finance.yahoo.com - January 25 at 6:39 AM
finance.yahoo.com logoIMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm (NASDAQ:TGTX)
finance.yahoo.com - January 25 at 6:39 AM
News IconNASDAQ:TGTX Investor News: Lawsuit alleges Misleading Statements by TG Therapeutics Inc (NASDAQ:TGTX)
www.groundreport.com - January 23 at 11:40 PM
us.rd.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 – TGTX (NASDAQ:TGTX)
us.rd.yahoo.com - January 23 at 11:40 PM
News IconTechnicals in Focus for TG Therapeutics Inc. (TGTX) - Sherwood Daily (NASDAQ:TGTX)
sherwooddaily.com - January 22 at 7:54 PM

Social

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Where is TG Therapeutics' stock going? Where will TG Therapeutics' stock price be in 2017?

7 brokerages have issued 1 year price targets for TG Therapeutics' shares. Their predictions range from $6.40 to $33.00. On average, they expect TG Therapeutics' stock price to reach $22.68 in the next twelve months.

When will TG Therapeutics announce their earnings?

TG Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:

  • According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (1/25/2017)

  • FBR & Co analysts commented, "We view the 6.7 months PFS for single agent mirvetuximab soravtansine in platinum resistant ovarian cancer as interesting when compared with 6.8 months for Avastin +chemotherapy in Phase 3. We acknowledge that the Immunogen data are Phase 1 vs. Phase 3 for Avastin and involve a small number of patients." (5/19/2016)

Who owns TG Therapeutics stock?

TG Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (6.93%), State Street Corp (1.24%), Eventide Asset Management LLC (0.98%), Guggenheim Capital LLC (0.49%), Teachers Retirement System of The State of Kentucky (0.29%) and A.R.T. Advisors LLC (0.10%). Company insiders that own TG Therapeutics stock include Sean A Power and William James Kennedy.

Who sold TG Therapeutics stock? Who is selling TG Therapeutics stock?

TG Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC.

Who bought TG Therapeutics stock? Who is buying TG Therapeutics stock?

TG Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Guggenheim Capital LLC, A.R.T. Advisors LLC, State Street Corp, Raymond James Financial Services Advisors Inc., Ellington Management Group LLC and Frontier Wealth Management LLC.

How do I buy TG Therapeutics stock?

Shares of TG Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TG Therapeutics stock cost?

One share of TG Therapeutics stock can currently be purchased for approximately $5.90.

TG Therapeutics (NASDAQ:TGTX) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Earnings History Chart

Earnings by Quarter for TG Therapeutics (NASDAQ:TGTX)

Dividend History Chart

Dividend Payments by Quarter for TG Therapeutics (NASDAQ:TGTX)

Last Updated on 2/26/2017 by MarketBeat.com Staff